Details of Drug Interaction | MecDDI

Drug General Information (ID: DDI8P05EWO)
Drug Name			Olmesartan		Drug Info		Amifostine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antihypertensive Agents				Cytoprotective Agent
Structure

Mechanism of Olmesartan-Amifostine Interaction (Severity Level: Moderate)
Additive hypotensive effects Click to Show/Hide Mechanism Graph

Drug Name		Olmesartan				Amifostine
Mechanism 1		Antihypertensive agent Angiotensin II receptor Antagonist				Antihypertensive agent
Key Mechanism Factor 1
		Factor Name		Angiotensin II receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Olmesartan and Amifostine
Mechanism 2		Antihypertensive agent Angiotensin II receptor Antagonist				Hypotensive effects
Key Mechanism Factor 2
		Factor Name		Angiotensin II receptor				Structure Sequence
		Protein Family		G-protein coupled receptor 1 family
		Protein Function		Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.; (Microbial infection) During SARS coronavirus-2/SARS-CoV-2 infection, it is able to recognize and internalize the complex formed by secreted ACE2 and SARS-CoV-2 spike protein through DNM2/dynamin 2-dependent endocytosis. Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Olmesartan and Amifostine

Recommended Action
Management		If medically feasible, antihypertensive medications should be interrupted 24 hours prior to amifostine administration. Blood pressure should be closely monitored during and after treatment. In addition to hypotension, transient hypertension or exacerbation of preexisting hypertension may occur from intravenous hydration, discontinuation of antihypertensive medications, or other causes. Patients who continue their hypotensive medication(s) during amifostine therapy should be carefully monitored for the development of hypotension.

References
1	Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
2	Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc, Markham, ON.
3	Product Information. Ethyol (amifostine). Alza, Palo Alto, CA.